Results 211 to 220 of about 274,980 (287)

Using sentiment analysis to quantify the relative desirability and acceptability of drug-product attributes. [PDF]

JAMIA Open
Calin C, Deligianni M, South BR, Jadhav A, Rocco M, Furqueron Z, Hauber B, Watt SJ.   +7 more
europepmc   +1 more source

Strategy for development of new and existing medicines for neuropathic pain: Results from a model based meta-analysis of summary level data from existing trials

Higgins, Tracy, Mandama, Jaap, Pfizer
core  

Predicting seizure freedom in the postpartum period: Findings from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether seizure freedom in pregnancy predicts seizure freedom in the postpartum period in women with epilepsy (WWE). Prior studies have shown that seizure freedom prior to conception strongly predicts seizure freedom during pregnancy.
Emma C. Osterhaus, Wesley T. Kerr, Kimford J. Meador, Jacqueline A. French, Angela K. Birnbaum, P. Emanuela Voinescu, Elizabeth Gerard, Page B. Pennell   +7 more
wiley   +1 more source

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. [PDF]

Blood Adv
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Martínez-López J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H.   +30 more
europepmc   +1 more source

PENICILLIN PFIZER [PDF]

Chemical & Engineering News Archive, 1944
openaire   +1 more source

Clinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy

Epilepsia, EarlyView.
Abstract Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction.
Valentina Franco, Francesca Dattrino, Michela Palmisani, Federica Tacchella, Elena Tartara, Valentina De Giorgis, Carlo Alberto Quaranta, Ludovica Pasca, Paola Rota, Emilio Russo, Andrea Romigi, Cecilie Johannessen Landmark, Guido Fedele, Cristina Tassorelli, Pierluigi Nicotera   +14 more
wiley   +1 more source

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. [PDF]

Future Oncol
Shore ND, Fizazi K, Schweizer MT, Castro E, Azad AA, George DJ, da Trindade KM, Zeng H, Shrivastava N, Tonkovyd S, Bock A, Nekkalapudi S, Tang Y, Lin S, Agarwal N.   +14 more
europepmc   +1 more source

Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Objectives To report disease‐free survival (DFS) in p16‐positive non‐oropharyngeal head‐and‐neck squamous‐cell carcinoma (HNSCC). Methods Curatively‐treated non‐oropharyngeal HNSCC (2009–2021) were reviewed. DFS was compared among p16‐positive, p16‐negative, and p16‐untested cases for the overall cohort and by disease site.
Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz‐Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron   +21 more
wiley   +1 more source

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer. [PDF]

NPJ Breast Cancer
Van Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, Blohmer J, Treue D, Schmatloch S, Lehmann A, Hanusch C, Link T, Sers C, Bjelic-Radisic V, Hummel M, Huober J, Schmitt WD, Fasching PA, Aktas B, Rhiem K, Reinisch M, Nekljudova V, Denkert C, Loibl S.   +24 more
europepmc   +1 more source

Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B. [PDF]

Blood Adv
Samelson-Jones BJ, Rasko JEJ, Ducore JM, McGuinn CE, George LA, von Mackensen S, Borgonuovo G, Agathon D, Smith L, Wilcox LJ, Biondo F, Plonski F.   +11 more
europepmc   +1 more source